Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 40 (3), 267-79

Modeling of PET Data in CNS Drug Discovery and Development


Modeling of PET Data in CNS Drug Discovery and Development

Katarina Varnäs et al. J Pharmacokinet Pharmacodyn.


Positron emission tomography (PET) is increasingly used in drug discovery and development for evaluation of CNS drug disposition and for studies of disease biomarkers to monitor drug effects on brain pathology. The quantitative analysis of PET data is based on kinetic modeling of radioactivity concentrations in plasma and brain tissue compartments. A number of quantitative methods of analysis have been developed that allow the determination of parameters describing drug pharmacokinetics and interaction with target binding sites in the brain. The optimal method of quantification depends on the properties of the radiolabeled drug or radioligand and the binding site studied. We here review the most frequently used methods for quantification of PET data in relation to CNS drug discovery and development. The utility of PET kinetic modeling in the development of novel CNS drugs is illustrated by examples from studies of the brain kinetic properties of radiolabeled drug molecules.

Similar articles

See all similar articles

Cited by 7 PubMed Central articles

See all "Cited by" articles


    1. Neuropsychopharmacology. 2003 Nov;28(11):2000-9 - PubMed
    1. Pharmacol Ther. 2009 Jun;122(3):281-301 - PubMed
    1. Eur J Clin Pharmacol. 2003 Sep;59(5-6):357-66 - PubMed
    1. Science. 1987 Jan 23;235(4787):481-5 - PubMed
    1. Mol Imaging Biol. 2005 Nov-Dec;7(6):377-87 - PubMed


LinkOut - more resources